• SENSEX
    NIFTY 50
Healthcare

Bharat Biotech cuts Covaxin Phase 2 trial size by half

Updated : October 14, 2020 09:16 AM IST

Two lead trial investigators told CNBC-TV18 that the decision was based on good seroconversion or immunogenicity seen in volunteers in Phase 1.
Out of 42 vaccines in clinical evaluation, 9 in late phase, only Bharat Biotech saw major change like cutting the size of Phase 2 trial.
Bharat Biotech cuts Covaxin Phase 2 trial size by half

You May Also Like

Live TV

recommended for you

Advertisement